¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody a."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • anticardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-double stranded deoxyribonucleic acid antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • anti-dsDNA antibody
    Ç×ÀÌÁß°¡´ÚDNAÇ×ü
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antimitochondrial antibody
    Ç×¹ÌÅäÄܵ帮¾ÆÇ×ü, Ç׻縳üÇ×ü
  • antineutrophil cytoplasmic antibody
    Ç×Áß¼º±¸¼¼Æ÷ÁúÇ×ü
  • antinuclear antibody
    Ç×ÇÙÇ×ü
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • antiphospholipid antibody
    Ç×ÀÎÁöÁúÇ×ü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀÓ±âÀü
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody-dependent cell-mediated cytotoxicity
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • antibody-mediated hypersensitivity
    Ç×ü¸Å°³°ú¹Î
  • antibody-mediated immunity
    Ç×ü¸Å°³¸é¿ª
  • antibody-producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antibody-screening cell
    Ç×ü¼±º°Ç÷±¸
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antinuclear antibody test
    Ç×ÇÙÇ×ü°Ë»ç
  • atypical antibody
    ÀÌÇüÇ×ü
  • autoimmune antibody
    ÀÚ°¡¸é¿ªÇ×ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • P antibody
    P Ç×ü
  • Scl-70 antibody
    Scl-70 Ç×ü
  • acetylcholine receptor antibody
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëüÇ×ü
  • acetylcholine receptor antibody assay
    ¾Æ¼¼Æ¿Äݸ°¼ö¿ëü Ç×Ã¼ÃøÁ¤
  • adcc(antibody dependent cell mediated cytotoxicity)
    Ç×üÀÇÁ¸¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º(ù÷ô÷ëîðíá¬øàØÚË¿á¬øàÔ¸àõ)
  • albumin agglutinating antibody
    ¾ËºÎ¹ÎÀÀÁýÇ×ü(¡­ëêó¢ù÷ô÷).
  • anti-La antibody
    Ç×LaÇ×ü
  • anti-RNP antibody
    Ç× RNPÇ×ü
  • anti-Ro antibody
    Ç× RoÇ×ü
  • anti-SM antibody
    Ç×SMÇ×ü
  • anti-cardiolipin antibody
    Ç×Ä«µð¿À¸®ÇÉÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • anti-sm antibody
    Ç×Sm Ç×ü(ù÷¡­ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈíÂø
  • antibody absorption test
    Ç×üÈí¼ö½ÃÇè(ù÷ô÷ýåâ¥ãËúÐ).
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antibody deficiency syndrome
    Ç×ü°áÇÌÁõÈıº(ù÷ô÷ÌÀù¹ñøý¦ÏØ).
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody detection
    Ç×ü°ËÃâ
  • antibody diversity
    Ç×ü´Ù¾ç¼º.
  • antibody excess
    Ç×ü°úÀ×(ù÷ô÷Φí¥).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody excess zone
    Ç×ü°úÀ×´ë(ù÷ô÷Φí¥Óá).
  • antibody feedback mechanism
    Ç×üµÇ¸ÔÀ̱â±âÀü.
  • antibody formation
    Ç×üÇü¼º(ù÷ô÷û¡à÷).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antibody titer
    Ç×ü¿ª°¡(ù÷ô÷æ³Ê¤)
  • antibody valence
    Ç×ü°¡(ù÷ô÷ʤ)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
  • anticomplement fluorescent antibody technique
    Ç׺¸Ã¼ Çü±¤Ç×ü¼ú(ù÷ÜÍô÷û«ÎÃù÷ô÷âú)
  • antigen-antibody complex
    Ç׿øÇ×ü º¹ÇÕü(ù÷ê«ù÷ô÷ ÜÜùêô÷)
  • antigen-antibody lattice
    Ç׿øÇ×ü °ÝÀÚ(ù÷ê«ù÷ô÷ Ì«í­)
  • antigen-antibody reaction
    Ç׿øÇ×ü ¹ÝÀÀ(ù÷ê«ù÷ô÷Úãëë)
  • bifunctional antibody
    ¾ç±â´É Ç×ü(å»Ñ¦Òö ù÷ô÷)
  • bispecific antibody
    ¾çƯÀ̼º Ç×ü(å»÷åì¶àõù÷ô÷)
  • blocking antibody
    Â÷´ÜÇ×ü(ó´Ó¨ù÷ô÷)
  • catalytic antibody
    Ã˸ÅÇ×ü(õºØÚù÷ô÷)
  • cold antibody
    ³ÃÇ×ü(Ò²ù÷ô÷)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • complete antibody
    ¿ÏÀüÇ×ü(èÇîïù÷ô÷)
  • coprecipitating antibody
    °øÄ§Àü(ÍìöØîþ) Ç×ü(ù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AIA allylisopropylacetamide; amylase inhibitor activity; anti-immunoglobulin antibody; anti-insulin anti...
ANA acetylneuraminic acid; American Narcolepsy Association; American Neurological Association; American ...
APA action potential amplitude; aldosterone-producing adenoma; Ambulatory Pediatric Association; America...
ATA alimentary toxic aleukia; American Thyroid Association; aminotriazole; antithymic activity; antithyr...
EA early antigen; educational age; egg albumin; electric affinity; electrical activity; electroacupunct...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
aCL Anti-cardiolipin antibody
ACA Anti-centromere antibody
AGA Anti-gliadin antibody
ANCA Anti-neutrophil cytoplasm antibody
ANA Anti-nuclear antibody
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • antiglobulin antibody
    Çױ۷κθ° Ç×ü
  • antiinsulin antibody
    Ç×Àν¶¸° Ç×ü
  • antinuclear antibody
    Ç×ÇÙ Ç×ü
    ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü·Î¼­ º¸Åë Àü½Å¼º È«¹Ý¼º ³¶Ã¢À» °¡Áø ȯÀÚÀÇ Ç÷û¿¡¼­ ¹ß°ßµÈ´Ù. ±×·¯³ª ·ù¸¶Æ¼¼º °üÀý¿°, °øÇÇÁõ ±×¸®°í ´Ù¸¥ °áÇÕÁ¶Á÷Àå¾Ö ȯÀÚ¿¡¼­µµ ¹ß°ßµÈ´Ù.
  • antiphospholipid antibody
    Ç×ÀÎÁöÁú Ç×ü
  • antiplatelet antibody
    Ç×Ç÷¼ÒÆÇ Ç×ü
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cellular antibody
    ¼¼Æ÷ Ç×ü
    ƯÀÌÀûÀÎ ¾Æ¹Ì³ë»ê ¹è¿­À» °¡Áø ¼¼Æ÷¼º ¸é¿ª ±Û·ÎºÒ¸° ºÐÀÚ.
  • circulating antibasement membrane antibody
    ¼øÈ¯ Ç×±âÀú¸· Ç×ü
  • cold reacting antibody
    ÇÑ·© Ç×ü
  • complement fixing antibody
    º¸Ã¼ °áÇÕ Ç×ü
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
antibody excess In a precipitation test, the presence of antibody in an amount greater than that required to combine with all of the antigen present.
(05 Mar 2000)
antibody-forming cell <immunology> B-cells (plasma cells) that are dedicated to producing secreted antibodies.
(09 Feb 1998)
antibody induced lysis <haematology> The term is imprecise and should not be used since there is confusion as to which mechanism is involved, i.e. Natural killing or complement lysis.
See: complement lysis, natural killer cells.
(09 Feb 1998)
antibody producing cell <immunology> A lymphocyte of the B series synthesising and releasing immunoglobulin. Equivalent to plasmacyte and plasma cell.
(18 Nov 1997)
antibody-producing cells Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesise.
(12 Dec 1998)
antibody specificity The property of antibodies which enables them to react with some antigenic determinants and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
(12 Dec 1998)
antibody technology <molecular biology> Techniques for the synthesis of polyclonal and monoclonal antibodies for use in research, diagnostics and therapeutics.
(09 Feb 1998)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
anti-idiotype antibody <immunology> An antibody directed against the antigen specific part of the sequence of an antibody or T-cell receptor and thus recognise the binding sites of other antibodies.
In principle an anti-idiotype antibody should inhibit a specific immune response and they are important to the regulation of the immune system.
(13 Nov 1997)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
antinuclear antibody <immunology> Antinuclear antibody is an antibody that react against components of the cell nucleus such as DNA, RNA, histone or non-histone proteins.
These antibodies are present in a variety of immunologic or autoimmune diseases including systemic lupus erythematosus, systemic sclerosis, scleroderma, Sjogren's syndrome, rheumatoid arthritis, polymyositis, dermatomyositis and in persons taking hydralazine, procainamide or isoniazid.
A serologic measurement for antinuclear antibodies can aid in the diagnosis of unexplained arthritis, rashes or chest pains.
Acronym: ANA
(12 Jan 1998)
anti-P antibody <haematology, investigation> A serologic blood test used to detect the Donath-landsteiner antibody in serum.
This test is performed in cases of suspected paroxysmal cold haemoglobinuria. A normal result is indicated by an absence of antibodies. The antibody is directed toward the P-antigen complex which is located on the surface of red blood cells. In some way, cold temperatures trigger the antibody to bind to this site.
(13 Jan 1998)
antiparietal cell antibody <immunology> A serologic blood test which measures the presence of antibodies to gastric parietal cells.
Less than 2% of the general population will be antibody positive although this can be higher in the elderly.
Approximately 90% of individuals with pernicious anaemia will be antibody positive. A positive result may also be seen in atrophic gastritis, gastric ulcer, thyroid disease, iron deficiency anaemia and diabetes.
(13 Jan 1998)
antiphospholipid antibody <immunology, syndrome> An uncommon disorder that is characterised by hypercoagulability due to the presence of antibodies against phospholipids.
These patients exhibit a tendency for recurrent and life-threatening thrombosis and embolic events (for example stroke). Individuals with antiphospholipid syndrome also have an increased tendency toward deep venous thrombosis, myocardial infarction and spontaneous abortions in females.
Antiphospholipid syndrome may be seen by itself or in association with other autoimmune illnesses (for example lupus) or with some infections.
Treatment includes long-term heparin and warfarin.
(13 Jan 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á